TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8387904
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 500 mg MK-886
Study: 8387904
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 250 mg MK-886 every 8 hours
Study: 2873133
Drug: thioridazine 800
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thioridazine 800 mg/day
Study: 29382036
Drug: BoNT/A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injections into four glands
Study: 29382036
Drug: BoNT/A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injections into three glands
Study: 29382036
Drug: BoNT/A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injections into two glands
Study: 29382036
Drug: BoNT/A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injections (overall)
Study: 24656867
Drug: Multimodal manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal manual treatment approach including analyzing treadmill with feedback, isokinetic dynamometric muscle strengthening, and balance retraining on dynamic balance platform
Study: 18443125
Drug: AMD3100 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD3100 therapy for 10 days
Study: 23820927
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg)
Study: 9811522
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis vaccine (DPT)
Study: 9811522
Drug: Acellular vaccines
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccines (DTaP‐12.5 and DTaP‐25)
Study: 3055672
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg decaris weekly (150 mg for 2 successive days) for 15 months (group 3)
Study: 3055672
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg decaris weekly (150 mg for 2 successive days) for 1 month (group I)
Study: 11156862
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/d)
Study: 15006009
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patches delivering 25 microg fentanyl/h (TTS‐fentanyl)
Study: 15006009
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and codeine (P/C)
Study: 8159516
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents for otitis media
Study: 8159516
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for sinusitis
Study: 15088527
Drug: Karinat (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karinat (2.5 mg beta-carotene, 5 mg alpha-tocopherol, 30 mg ascorbic acid, 150 mg garlic powder, one tablet twice a day for 6 months)
Study: 15088527
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet twice a day for 6 months)
Study: 8232766
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (10 mg/kg, p.o. at 8.00 h)
Study: 25850966
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg, intravenous)
Study: 14758376
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ciprofloxacin drops intraoperatively
Study: 18294482
Drug: Dalteparin treatment
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin treatment
Study: 11251353
Drug: Continuation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation with dalteparin therapy after revascularization procedures
Study: 9489063
Drug: Clomipramine (25‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25‐150 mg daily)
Study: 9489063
Drug: Dothiepin (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75‐150 mg daily)
Study: 7871037
Drug: Diazepam (FAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (FAST condition) - 20 mg single dose
Study: 7871037
Drug: Diazepam (SLOW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (SLOW condition) - 6 doses of 4 mg administered at 30-min intervals
Study: 3544648
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg, intramuscular injection)
Study: 3544648
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg, intramuscular injection)
Study: 29785686
Drug: Positive framing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive framing group (informed that dizziness is a sign that the drug had started to work)
Study: 25363175
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg three times a day)
Study: 25363175
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg every other week for up to 12 sessions)
Study: 25363175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pentoxifylline and Verapamil)
Study: 15987536
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for 10 days
Study: 12494614
Drug: Model 6944
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 6944 (small-surfaced, steroid-eluting electrode tip)
Study: 12494614
Drug: Model 6942
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 6942 (conventional sized, steroid-eluting electrode tip)
Study: 2562095
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of a local anesthetic solution containing 0.5% bupivacaine and 0.15 mEq of NaHCO3 (Group I)
Study: 23220013
Drug: i.v. busulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. busulfan at a dose of 11.2 mg/kg/d
Study: 23220013
Drug: other doses
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: other doses of busulfan
Study: 19920000
Drug: Daily school
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily school exercise lessons for 1 year
Study: 19920000
Drug: Regular school
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular school sports twice weekly
Study: 9990360
Drug: Calcipotriol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol treatment for 4 and 7 days
Study: 8615060
Drug: Calcipotriol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol treatment
Study: 8090631
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment of hyperthyroidism (0.81 GBq)
Study: 8090631
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment of differentiated thyroid cancer (1.85 GBq)
Study: 17985826
Drug: Aquaphor Original
Normalized name: Aquaphor Original Severely Dry Skin 41% Topical Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquaphor Original Emollient Ointment
Study: 16131946
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pharmacotherapy and psychotherapy)
Study: 7594099
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (specific agent not mentioned); administered during menstruation.
Study: 2178930
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide 5-mononitrate (ISMN)
Study: 378053
Drug: Intranasal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroid aerosol (beclomethasone dipropionate)
Study: 27993169
Drug: Standardized exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized exercise prescription (HRR)
Study: 12012144
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (60 mg) under fasted conditions
Study: 10523801
Drug: 1600 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg/d oral clodronate
Study: 2140330
Drug: Josamycin 1000
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin 1000 mg twice daily for a maximum of 14 days
Study: 21192153
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (36 mg/d to 108 mg/d)
Study: 7755380
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with adreno-oophorectomy
Study: 7755380
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy with FAC
Study: 7910470
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg suriclone
Study: 6968611
Drug: Bulk laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxative and a large anal dilator
Study: 6968611
Drug: Bulk laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxative only
Study: 16032934
Drug: HFA‐BDP 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP 160 mcg twice daily
Study: 10653204
Drug: Clonazepam 1
Normalized name: clonazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1 mg and Placebo (CZ + PL)
Study: 10653204
Drug: Clonazepam 1
Normalized name: clonazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1 mg and Sertraline 100 mg (CZ + SR)
Study: 8559528
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) tablets (3 mg)
Study: 8559528
Drug: Oxytocin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (continuous intravenous drip)
Study: 6880563
Drug: Chlorpropamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (250 mg) administered once
Study: 6880563
Drug: Repeated administrations
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days)
Study: 6880563
Drug: Metergoline (antiserotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (antiserotonin agent) and bromocriptine (dopamine-agonist)
Study: 22192246
Drug: saxagliptin +
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saxagliptin + metformin XR 1500 mg
Study: 22192246
Drug: uptitrated metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: uptitrated metformin XR 2000 mg
Study: 12325487
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 150 mg APD
Study: 10404554
Drug: Daily cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cigarette consumption scenarios with varying nicotine concentrations
Study: 1974070
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg alpidem
Study: 1974070
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg alpidem
Study: 2883214
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alpidem
Study: 29963684
Drug: Topical aminolaevulinic
Normalized name: aminolevulinate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aminolaevulinic acid-photodynamic therapy with green light
Study: 29963684
Drug: Topical aminolaevulinic
Normalized name: aminolevulinate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aminolaevulinic acid-photodynamic therapy with red light
Study: 21684602
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy in female participants
Study: 2906017
Drug: Celiprolol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol, 400 mg once daily
Study: 24564933
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d prednisone added to MTX-based tight control strategy
Study: 22616908
Drug: Sitafloxacin (STFX)
Normalized name: Finafloxacin
DrugBank: Sitafloxacin (DB13261)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sitafloxacin (STFX) 100 mg/day for 5 days
Study: 15702819
Drug: Fluticasone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (250 microg twice daily)
Study: 2816875
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg/6 h
Study: 2816875
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg/4 h
Study: 2816875
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine 0.2 mg/kg/h
Study: 2816875
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cimetidine 100 mg/h
Study: 31455249
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL ropivacaine 0.75%
Study: 31455249
Drug: 16 mL
Normalized name: 16 ML Mvasi 25 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mL ropivacaine 0.75%
Study: 31455249
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (8 mL and 16 mL)
Study: 23736966
Drug: Voclosporin (VCS)
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voclosporin (VCS) 3.0 mg/kg
Study: 19520544
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mL)
Study: 19520544
Drug: Saline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (20 mL, Control)
Study: 17848841
Drug: Reference rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference rhGH preparation
Study: 11831591
Drug: Dialysate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate with a glucose concentration of 5.5 mmol/L
Study: 11831591
Drug: Dialysate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate with a glucose concentration of 11 mmol/L
Study: 2966139
Drug: Flucloxacillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin (500 mg qds for five days) and Tobramycin (1.5 mg/kg initially then 80 mg tds for three days)
Study: 329948
Drug: Atenolol, Bendrofluazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, Bendrofluazide, and Hydralazine (twice daily)
Study: 329948
Drug: Atenolol and
Normalized name: atenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol and Bendrofluazide (once daily)
Study: 17610527
Drug: PC-SOD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD 20 mg
Study: 17610527
Drug: PC-SOD 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD 40 mg
Study: 17610527
Drug: PC-SOD 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD 80 mg
Study: 31599225
Drug: PC-SOD 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD 160 mg
Study: 18676075
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg/d
Study: 273021
Drug: Sequential t
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential t test
Study: 21055502
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HA
Study: 21055502
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg HA
Study: 16464538
Drug: Hyperfractionated and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated and accelerated radiochemotherapy (RCT) with 5-fluorouracil (600 mg/m²/day) and carboplatin (70 mg/m²/day) on Days 1-5 and 29-33, total RT dose of 69.9 Gy in 38 days.
Study: 9071477
Drug: Tiludronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiludronate (400 mg/day orally)
Study: 29053230
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: One‐off face‐to‐face biofeedback treatment
Study: 20054669
Drug: Response-oriented individualized
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-oriented individualized induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Study: 20054669
Drug: Fixed-schedule induction
Normalized name: Humalog Mix Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Study: 12399761
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser treatment, 3 times per week for up to 8 weeks
Study: 15313811
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser treatment
Study: 10435212
Drug: Lorazepam (LO)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LO) 2 mg
Study: 10435212
Drug: Oxazepam (OX)
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam (OX) 60 mg
Study: 24938661
Drug: Iosimenol injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iosimenol injection
Study: 24938661
Drug: Iodixanol injection
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol injection
Study: 14507232
Drug: Botox® (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox® (total dose 20 biological units)
Study: 24114400
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate 1 g/day
Study: 26307050
Drug: Intracytoplasmic morphologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic morphologically selected sperm injection (IMSI)
Study: 15900109
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at dosages of 4 IU/m2/day, 6 IU/m2/day, or 8 IU/m2/day for a mean duration of 7.1 (0.4) years.
Study: 8593549
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (12 micrograms vitamin D3 and 1525 mg calcium per litre)
Study: 8593549
Drug: Unfortified milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfortified milk (0.3 micrograms vitamin D3 and 1270 mg calcium per litre)
Study: 337903
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen (0.6 mg/kg) and sunlight exposure
Study: 19100304
Drug: 7-valent conjugated
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugated pneumococcal vaccine (PCV7)
Study: 19100304
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (23vPPV)
Study: 16885405
Drug: Adiponectin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin (mean +/- SD 12.8 +/- 8.0 mug/ml)
Study: 12527148
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (group A)
Study: 1739854
Drug: Memory remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory remediation treatment (compensatory and executive training skills), delivered 6 hours weekly over a 2 1/2‐week period
Study: 27652199
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive SIJ fusion with triangular titanium implants (SIJF)
Study: 21623930
Drug: Tapering TC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering TC regimen (3/week for 1st month, 2/week for 2nd month, 1/week for 4th month)
Study: 21623930
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (twice weekly and tapering)
Study: 18953611
Drug: Preoperative imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative imatinib (600 mg daily for 3, 5, or 7 days)
Study: 11696123
Drug: midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.5 mg.kg(‐1)
Study: 9312763
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/night
Study: 30672432
Drug: 50% field
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% field capacity irrigation treatment
Study: 27399956
Drug: 0.05 mL
Normalized name: xenon 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mL injection volume of abobotulinumtoxinA (10 Speywood units)
Study: 25407349
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication reviews (CMRs)
Study: 18403223
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of ipratropium and albuterol (IB+ALB)
Study: 18403223
Drug: Albuterol alone
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol alone (ALB)
Study: 10885682
Drug: Methylphenidate (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10, 25, 20 mg doses)
Study: 9289443
Drug: Kliogest hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kliogest hormone therapy
Study: 1521669
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg mexiletine
Study: 23283585
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.5 Gy